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ABSTRACT
Objective: We evaluated the prevalence of positive po-
tassium sensitivity and cystoscopy with hydrodistention
findings in patients with overactive bladder.
Method: This was a prospective cohort study of 98 pa-
tients who presented with overactive bladder symptoms.
The diagnosis of overactive bladder is established by the
presence of irritable voiding symptoms. All patients com-
pleted a PUF questionnaire and underwent potassium
sensitivity testing. Eighty patients underwent urodynamic
testing, and 42 patients underwent cystoscopic hydrodis-
tention while under general anesthesia.
Results: The Potassium Sensitivity Test was positive in 59
(60.2%) of the 98 patients, 37 (56%) of wet overactive blad-
der patients, and 22 (68.8%) of dry overactive bladder pa-
tients. Their mean PUF score was 7. Thirty-three (78.5%) of
the patients who underwent cystoscopic hydrodistention
had glomerulations consistent with NIH criteria for interstitial
cystitis, and 26 of these patients tested positive for potassium
sensitivity. Fifty-one (63.8%) of the patients who underwent
urodynamics tested positive for potassium sensitivity.
Conclusion: Many patients with symptoms of overactive
bladder with little or no pain have cystoscopic evidence of
interstitial cystitis and a positive Potassium Sensitivity Test.
Therapies directed toward the uroepithelial dysfunction
and neural upregulation associated with interstitial cysti-
tis/painful bladder syndrome may be an important adjunct
for patients who have failed or have had a partial response
to anticholinergic therapy and behavior modification.
Key Words: Overactive bladder, Interstitial cystitis/pain-
ful bladder syndrome, Cystoscopy, Hydrodistention, Po-
tassium Sensitivity Test.
INTRODUCTION
Overactive bladder (OAB) was recently defined by the In-
ternational Continence Society as “urgency, with or without
urge incontinence, usually with frequency and nocturia. . . if
there is no proven infection or other obvious pathology.”1
Furthermore, there is a long list of associated disorders that
can cause these symptoms to develop. Therapy that is symp-
tom based is often very effective, but there are times when
this management plan can be inadequate.
During the last decade, our knowledge of the neural
pathways involved in the control of the lower urinary tract
has been greatly expanded. The control of the lower
urinary tract is dependent on input from the lower urinary
tract and the pelvic floor into the central nervous system
(CNS). Control is regulated both within the spinal cord
(sacral micturition center) and within supraspinal areas
(pons micturition center). Proposed factors involved in
the pathophysiology of overactive bladder include neuro-
genic and/or myogenic causes. Possible factors associated
with a neurogenic cause include damage to central neu-
rologic pathways leading to a loss of peripheral inhibition,
reduced suprapontine inhibition, injury to axons within
the spinal cord, increased lower urinary tract afferent
output, and enhancement of excitatory neurotransmission
within the micturition reflex pathways. In recent years,
our interest in the pathophysiology of overactive bladder
has shifted from the detrusor muscle to the afferent inner-
vation of the lower urinary tract. With this shift, we have
opened the door to improved understanding of the symp-
toms of overactive bladder in patients who have a com-
ponent of their pathology arising from the afferent arm of
the lower urinary tract and pelvic floor innervation. This
new understanding will provide more options in the man-
agement of these complicated patients as well.
Interstitial cystitis (IC), also known as painful bladder syn-
drome (PBS),2 is a clinical syndrome of urinary urgency,
frequency, pelvic pain, or combination of all of these3,4
without an obvious identifiable cause, ie, infection, neoplas-
tic process, and others. Symptom flares are often associated
with sexual relations, menstrual cycle, certain types of foods,
and stress. Given that the primary symptoms are sensory
based–urgency, frequency, and pain–a conclusion can be
drawn that these patients’ symptoms would arise from an
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SCIENTIFIC PAPERupregulated afferent output from the lower urinary tract. If
this is true, then one would expect an overlap between the
diagnosis of overactive bladder and the diagnosis of intersti-
tial cystitis in a portion of patients who present with overac-
tive bladder symptoms.
This study examined that potential overlap by using a symp-
tom-based diagnosis of overactive bladder and 2 common
tools to diagnose interstitial cystitis/painful bladder syn-
drome: the potassium sensitivity test (PST) and cystoscopy
with hydrodistention. It is our belief that many patients have
overactive bladder due to an overactive afferent arm of their
micturition reflex and would benefit from therapies directed
toward this upregulation. Discussion will follow that further
reviews the potential that interstitial cystitis is in fact a visceral
pain syndrome that has afferent upregulation as a key com-
ponent to its pathophysiology.
METHODS
Of the 532 women treated at The Midwest Regional Center
for Chronic Pelvic Pain and Bladder Control in Lima, Ohio
from October 2000 to October 2002, 98 women (18 to 62
years old) were diagnosed with overactive bladder. These 98
patients did not report pelvic pain as part of their symptoms.
Some of the women were initially treated by their family
physicians with anticholinergic medication and failed to
have satisfactory improvement in symptoms. All 98 patients
fit the diagnosis of overactive bladder according to the stan-
dard definition of having urinary urgency (sensation of in-
complete emptying of the bladder), frequency of at least 8
times in 24 hours, and nocturia, with or without incontinence
for more than 6 months in duration.5–8
All 98 patients had laboratory studies carried out including
urinalysis, urine cytology, urine culture, and a cervical
Ureaplasma culture. All tests came back negative. These
patients also had negative abdominal and pelvic exami-
nations that indicated that their lower abdomen, pelvic
floor, and bladder were not tender.
All patients were then tested for potassium sensitivity as
described by Parsons.9 In this test, the patient was asked
to rate her pain level and sensation of urgency at 3 points:
her initial baseline pain level prior to the infusion of 40 mL
of sterile water (solution A) into her bladder, after solution
A was retained for 3 to 5 minutes, and after solution A was
drained and 40 mL of a 400 mEq/L solution of potassium
chloride (solution B) was infused into the bladder. The
patient was asked to rate her symptom according to the
degree of provocation of urgency and pain on a scale of 0,
indicating no provocation, to 5, indicating marked prov-
ocation (Figure 1). A positive test was defined by a
change in score of 2 or more from the baseline.
In addition to the PST, all women were given the PUF
questionnaire4 (Figure 2).
All patients were offered a urodynamic evaluation. Eighty
of the cohort had a urodynamic evaluation, and 42 pa-
tients received cystoscopy and hydrodistention of the
bladder while under general anesthesia. The patients who
underwent cystoscopy and hydrodistention either had se-
vere symptoms or chose not to be on pentosan polysulfate
unless an IC diagnosis was made. The bladder hydrodis-
tention was carried out by applying 80 cm to 100 cm of
passive hydrostatic pressure using sterile water. The blad-
der was distended for at least 2 minutes before the water
was slowly drained out. The submucosal petechiae hem-
orrhages, also known as glomerulations, were observed
as the bladder was being emptied or during the second
fill. An interstitial cystitis diagnosis was made according to
the NIH guidelines by noting the presence of 10 glomeru-
lations per quadrant in 3 of the 4 quadrants of the bladder
cavity and the presence of terminal hematuria.
The researchers were blind to the findings of the potas-
sium sensitivity test, PUF questionnaire, and cystoscopy
and hydrodistention.
RESULTS
There were 532 patients evaluated through the pelvic pain
center; 98 women (18.4%) had a diagnosis of overactive
bladder (OAB). Of these 98 women, 59 (60.2%) had a
positive potassium sensitivity test; 39 (39.8%) had a negative
test. The average PUF score was 7 for all of the 98 patients.
Eighteen patients chose not to go through with urody-
namic testing due to personal reasons, and 80 patients
underwent urodynamic testing. In this group of patients,
the average first sensation (1S) was 59 mL, and their
average cystometric bladder capacity was 480cc.
Fifty-one (63.75%) women in this group had a positive
potassium sensitivity test. The first sensation (1S) for these
women who tested positive was 56 mL and their average
cystometric bladder capacity was 465 mL.
Only 42 patients underwent cystoscopic hydrodisten-
tion. Thirty-three (78.5%) patients were found to have
glomerulations consistent with the NIH criteria for in-
terstitial cystitis, and 31 (73.8%) of the 42 women had a
positive PST; 26 (61.9%) of the 42 patients had both a
positive PST and positive cystoscopic findings; 5
(11.9%) patients had a positive PST but negative cys-
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positive cystoscopic findings. Four of the 42 (9.4%)
patients were negative for both PST and cystoscopy.
The average first sensation (1S) for the groups with
positive potassium sensitivity and cystoscopic finding
was 40 mL, and their cystometric bladder capacity was
440 mL. Their average bladder capacity while under
general anesthesia was 1000 mL. These 42 patients had
a mean PUF score of 8.
Of the 98 patients with OAB, 66 (67.3%) had urinary
incontinence, and 37 (56%) of these patients had a posi-
tive potassium sensitivity test (Figure 3). The breakdown
of this urinary incontinence group included 17 patients
(17.35%) exhibiting true detrusor instability and 49 (50%)
patients with stress incontinence in addition to urgency,
frequency, and nocturia.
In the group of 17 OAB patients (17.35%) who presented
with true detrusor instability (Figure 4), only 8 patients (47%)
tested positive for potassium sensitivity, and 7 women (41.2%)
had a positive cystoscopic finding for interstitial cystitis.
Of the 49 women (50%) with OAB and stress urinary
incontinence (Figure 5), 29 women (59%) had a positive
potassium sensitivity test.
POTASSIUM SENSITIVITY TEST (PST)
Name:__________________________________   Date:__________________  Age:_______
URGENCY today: 0     1     2     3     4     5 PAIN today:   0     1     2     3     4     5
SOLUTION A:
1. How much urgency to urinate do you have now compared to before the solution was 
placed?  (Choose from 0 to 5)
     ONSET
        none          moderate                severe Grad     Immed
012345
2. How much pain do you have now compared to before the solution was placed?  (Choose 
from 0 to 5)
     ONSET
        none          moderate                severe Grad     Immed
012345
SOLUTION B:
1. How much urgency to urinate do you have now compared to before the solution was 
placed?  (Choose from 0 to 5)
     ONSET
        none          moderate                severe Grad     Immed
012345
2. How much pain do you have now compared to before the solution was placed?  (Choose 
from 0 to 5)
     ONSET
        none   moderate                severe Grad     Immed
012345
3. If no pain noted in (2) above, have the patient void potassium and rate any perceived pain 
below.  (Choose from 0 to 5)
        none          moderate                severe
012345
Which solution felt worse? A        B        Neither   (please circle one)
Is  A  or  B?     Mild       Moderate       Severe   (please circle one)
Vol. water IN: _____  Vol. water OUT: _____  Vol. KCl IN: _____  Vol. KCl OUT:_____
Figure 1. Potassium sensitivity test.
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urinary urgency, frequency, and nocturia (Figure 6).
Twenty-two (68.75%) patients in this group had a positive
potassium sensitivity test. (Table 1).
DISCUSSION
Overactive bladder is a highly prevalent disorder that
impacts millions of people worldwide. Despite the ad-
PELVIC PAIN and URGENCY/FREQUENCY
PATIENT SYMPTOM SCALE
Patient’s Name: ___________________________________ Today’s Date: _______________
Please circle the answer that best describes how you feel for each question.




1 How many times do you void during the 
waking hours? 3-6 7-10 11-14 15-19 20+
2 a.  How many times do you void at
     night? 01 2 3 4 +
b.  If you get up at night to void, to
      what extent does it usually bother
     you?
None Mild Moderate Severe
3 Are you currently sexually active.
        YES _____      NO_____
4
a.  IF YOU ARE SEXUALLY
     ACTIVE, do you now or have
     you ever had pain or symptoms
     during or after sexual intercourse?
Never Occasionally Usually Always
b.  Has pain or urgency ever made
     you avoid sexual intercourse? Never Occasionally Usually Always
5
Do you have pain associated with your 
bladder or in your pelvis (vagina, lower 
abdomen, urethra, perineum)?
Never Occasionally Usually Always
6 Do you still have urgency shortly
after urinating?  Never Occasionally Usually Always
7 a.  If you have pain, is it usually Mild Moderate Severe
b.  How often does your pain bother
     you? Never Occasionally Usually Always
8 a.  If you have urgency, is it usually Mild Moderate Severe
b.  How often does your urgency
     bother you? Never Occasionally Usually Always
SYMPTOM SCORE   (1, 2a, 4a, 5, 6, 7a, 8a)    
BOTHER SCORE  (2b, 4b, 7b, 8b)    
TOTAL SCORE  (Symptom Score + Bother Score)  =
Figure 2. Pelvic pain and urgency/frequency patient symptom scale questionnaire.
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the majority of patients with overactive bladder have some
persistent symptoms even though their quality of life
might in fact be improved and their urgency, frequency,
and incontinence reduced. Although a symptom-based
diagnosis lends itself to a higher number of patients re-
ceiving care as a result of a simplified treatment algorithm,
it must be realized that not all patients will respond to this
initial management. When this occurs, the clinician must
recognize that other causes need to be considered, and
these will lead to new treatment options.
At this time, we are unable to predict by history alone, but
as clinicians we must remember that symptoms of OAB
and IC/PBS are the result of various triggers, and the main
clinical difference is generally the presence or absence of
pain. But the symptoms are the final expression of various
and overlapping pathologies at the urothelium, bladder
wall, pelvic floor, and central processing. Management is
presently based on a symptom-based diagnosis, but espe-
cially in patients with less than adequate response to
therapy, we must consider other pathologies. The PST
may identify a subgroup of patients with urothelial dys-
function and/or C-fiber upregulation that may benefit by
targeting these pathologies rather than the muscarinic
receptor alone (ie, anticholinergic drugs).
The debate as to how to diagnose interstitial cystitis con-
tinues to grow and like overactive bladder, interstitial
cystitis/painful bladder syndrome is increasingly thought
to be a clinical syndrome that can easily be diagnosed.10
Additionally, it is increasingly being diagnosed in many
patients who suffer from common pain disorders, eg,
vulvodynia, chronic pelvic pain, endometriosis, fibromy-
algia, and functional bowel disease.11,12 Many causes of
interstitial cystitis have been proposed, including infec-
tion, neurogenic, autoimmune, GAG layer dysfunction,
and mast cell abnormalities, but these changes may be a
reflection of end-organ effect and not the primary pathol-
ogy. The end result of all of these potential etiologies is an
upregulation of sensory output from the bladder and/or
Figure 3. Potassium sensitivity test results for overactive bladder
patients (n98).
Figure 4. Potassium sensitivity test results for overactive bladder
patients with detrusor instability (n17).
Figure 5. Potassium sensitivity test results for wet overactive
bladder patients with urinary urgency, urinary frequency, noc-
turia, and stress urinary incontinence (n49).
Figure 6. Potassium sensitivity test results for dry overactive
bladder patients with urinary urgency, urinary frequency, and
nocturia (n32).
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cral cord. These changes are the hallmark of any visceral
pain syndrome. Many of these patients can progress to
develop global hypersensitivity and show abnormal signal
processing in the suprasacral areas, eg, limbic system,
insular and thalamus.
Current theories of the pathophysiology of interstitial cys-
titis are predominantly conjecture, but increasingly au-
thors are describing IC as simply a form of a visceral pain
syndrome.13 Visceral pain syndromes involve chronic
neurogenic inflammation, primary afferent overactivity,
and central nervous system sensitization that all interact to
perpetuate pain.14 The bladder is an ideal organ to induce
this dysregulation of dorsal horn activity because it has the
highest neural density of any pelvic organ.15 The majority
of the afferent nerves arising from the bladder are silent,
but with prolonged stimulation (and this can occur with
many types of insults), these silent C-fibers can become
active.16 This new barrage of nociceptive or painful input
onto the dorsal horn initiates a series of biochemical
changes that can become permanent (often referred to as
central sensitization), depending on the duration and se-
verity of the input. These changes result in a decrease in
the threshold (the amount of stimulus needed to be per-
ceived as painful) within the dorsal horn.17 This alteration
in sensory processing results in a phenomenon known as
allodynia. This is exemplified in patients whose bladders
feel painfully full and urgent at a volume of only 3oz.
These changes are collectively referred to as spinal cord
windup and are an example of abnormal neuronal plas-
ticity.18,19
As noted above, bladder C-fibers are typically silent and
are activated not by volume, but by cold and/or chemical
irritation.20 This physiologic characteristic is the key to
understanding the importance of the potassium sensitivity
test. The C-fibers are located within the uroepithelium and
submucosa of the bladder. If the protective effects of the
glycosaminoglycan (GAG) layer are somehow deficient,
the potasium ions will depolarize and/or activate the C-
fibers; thus, a positive PST will be demonstrated. A posi-
tive PST can therefore occur from increased permeability
of the urothelium, from an increase in activated C-fibers,
or from a combination of both. The etiology of OAB is
diverse and involves release of acetylcholine from nerve
fibers and bladder urothelium, as well as the release of
ATP. Both these events occur as a result of bladder wall
stretch, inflammation, and pH changes. Spontaneous
myogenic activity and neuroplasticity often occur as
well.21 ATP release from the urothelium is upregulated in
various clinical situations including where patients are
65 years of age and where OAB is present and in feline
interstitial cystitis.22 PZX3 receptors (1 of the 7 subtypes of
ATP receptors) are involved in this reaction and are also
involved in both nociceptive and non-nociceptive afferent
pathways. The fact that the urothelium has been found to
have sensory function and is involved in normal and
abnormal sensory processing is the key to understanding
that there is symptomatic as well as neuropathologic over-
lap in patients with OAB and IC.
We have shown that 60% of patients with overactive
bladder symptoms have evidence of a positive PST. This
suggests that these patients have a deficiency in the GAG
layer and/or an increase in activated C-fibers. Addition-
ally, many authors9,23–25 have shown that a positive PST
correlates with a diagnosis of interstitial cystitis In the
patients with an overactive bladder who also underwent
cystoscopy with hydrodistention, we found that 73.8%
have cystoscopic evidence compatible with interstitial cys-
titis, and 61.9% of these same patients have both a positive
PST and cystoscopic findings compatible with interstitial
cystitis. These data emphasize that patients with overac-
tive bladder often have pathology that would best be
managed with therapy directed towards the interstitial
cystitis/painful bladder syndrome component (afferent
upregulation and urothelial dysfunction) rather than using
only muscarinic blockade, ie, anticholinergic therapies.
Table 1.
Potassium Sensitivity Test Results for Overactive Bladder Patients
All Patients Urinary Incontinence Patients CH*
(n98) UU/UF/N* (n32) UU/UF/N  SUI* (n49) DI* (n17) ()C H( n 33) (-) CH (n9)
() PST* 59 22 29 9 26 5
(-) PST 39 10 20 8 7 4
*PST  potassium sensitivity test; UU  urinary urgency; UF  urinary frequency; N  nocturia; SUI  stress urinary incontinence; DI
 detrusor instability; CH  cystoscopic hydrodistention
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found that 56% of the patients with urinary incontinence
or wet overactive bladder had a positive PST, while
68.75% of the dry OAB patients exhibiting only urinary
urgency, frequency, and nocturia had a positive PST. The
higher incidence of positive PST in patients with dry
overactive bladder suggests that interstitial cystitis/painful
bladder syndrome could be a contributing factor in the
symptoms of these patients. Clinical research has shown
that the use of anticholinergic drugs for the treatment of
overactive bladder symptoms reduces urinary urgency by
about 60%, reduces micturition frequency by about 25%,
and reduces urinary incontinence by about 80%.26–28
These data support the notion that dry OAB patients have
symptoms that would be better managed with therapy
directed towards interstitial cystitis/painful bladder syn-
drome. It has recently been demonstrated in a randomized
2-year study of 82 patients with OAB that 0.2% chon-
droitin sulfate installation provided much better response
than Tolterodine provided (73% vs 43% at 12 months and
56% vs 14% after 24 months) after 12 months of therapy.29
The prolonged benefit of this glycosaminoglycan supple-
ment demonstrates the importance of correcting urothelial
dysfunction in patients who have a poor response to
anticholinergics alone. Whether the label applied to a
particular patient is IC/PBS or remains OAB is controver-
sial but our inability to establish an appropriate label
should not limit the therapies we offer.
CONCLUSION
Many patients with symptoms of overactive bladder were
found to have cystoscopic findings of interstitial cystitis/
painful bladder syndrome and a positive PST. Given the
multiple pathophysiologic causes of overactive bladder, it
should not surprise us that some patients have evidence of
C-fiber upregulation (positive PST). These findings en-
courage us to realize that patients who have failed tradi-
tional therapies for overactive bladder might be more
effectively treated using therapies directed towards the
uroepithelial dysfunction30 and neural upregulation asso-
ciated with interstitial cystitis.31
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